At the news
? BULLISHIMPACT 7/10 PRESS-RELEASE filed Aug 5, 2026 at 07:30 ET
Bioventus reported Q2 2026 revenue of $153.2M (+4% YoY), slightly below the $155.6M consensus, and Non-GAAP EPS of $0.22, exactly in line with estimates. Full-year guidance was reaffirmed. However, the headline event is the formal initiation of a strategic alternatives review after receiving an unsolicited acquisition proposal, with Evercore and Latham & Watkins retained. This creates a near-term catalyst for a potential premium takeout, making the earnings results secondary.
- Q2 revenue $153.2M (+4% YoY), consensus $155.6M (miss but within 2%)
- Non-GAAP EPS $0.22, in line with $0.22 consensus
- Full-year 2026 guidance reaffirmed: revenue $600M-$610M, Adjusted EPS $0.75-$0.79, cash from ops $84M-$89M
- Board initiated formal strategic alternatives review after unsolicited acquisition proposal
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access